Pain Research and Management

Review Article

Patient Preferences and Values in Decision Making for Migraines: A Systematic Literature Review

Table 2

The preventive treatment of migraine.
StudyDateCountryStudy designSimple sizeMigraine statusTreatmentMethodScore
DrugUsageDurationCostSide effect
Cowan et al. [17]2016–2017AmericanCross-sectional417≥1 d/mA new class of biologicsSubcutaneous injectionAdminister monthly or quarterlyDisregardedUnclearRanking9
Mansfield et al. [18]February and May, 2017AmericanCross-sectional100≥6 d/m Injection or oral pillOnce/m, once/d, twice/m$5–$175/mYesSG10
Kol et al. [19]2008aNetherlandsCross-sectional151 Triptans, analgesics   YesSG9
Peres et al. [20]2007aAmericanCross-sectional250≥12 m/yβ-blockers, calcium channel blockers, antidepressants, antiepileptics, neurotoxins Once/3 m, once/d, twice/dOut-of-pocket expenseYesRanking8
Kelman [21]2006aAmericanProspective study1750     YesInterviews8
Rozen [22]2006aAmericanCross-sectional150 Analgesic, natural therapy    Ranking9
Wenzel et al. [23]September to November, 2002AmericanCross-sectional22 Over the counter Once/dLow price Ranking9
Lipton and Stewart [24]1998AmericanCross-sectional688  Capsule, subcutaneous injection  YesInterviews7
Adelman et al. [25]January to June, 1999AmericanProspective study367 RizatriptanDisintegrating tablet, conventional tablet.10 mg/d, 6 m  Interviews8
Pascual et al. [26]2001aSpainCase-control study94 Sumatriptan, zolmitriptanOral tablet50 mg, 2.5 mg  Ranking8
Weidmann et al. [27]2003aAmericanCase-control study332–6 d/mSumatriptanOral, intranasal, subcutaneous $45YesRanking9
Dahlöf et al. [28]2002–2003SwedenCase-control study232Acute attackedZolmitriptanOral, intranasal, subcutaneous5 mg, 6 consecutive YesTTO9
Lipton et al. [29]2005aAmericanCross-sectional415 TriptanOral  YesTTO8
Schoenen et al. [30]2005aAmericanCase-control study323Acute attackedEletriptan or sumatriptanOral, subcutaneous80 mg, 6 mg YesTTO8
Lainez et al. [31]2001–2002ItalyCase-control study372Acute attackedRizatriptan, eletriptan 10 mg/40 mg  TTO9
Dowson et al. [32]2007aUnited KingdomProspective study481–4 d/mZolmitriptanOral2.5 mg, 5 mg; 10 m  TTO8
Diez et al. [33]2007aItalyProspective study4362–6 d/mRizatriptan, almotriptan 12.5 mg, 10 mg YesTTO9
Lanteri et al. [34]2003FranceProspective study17106 d/1.5 mTriptans, analgesics, ergot derivatives    Ranking9
Bartolini et al. [35]2011aItalyRandomized controlled1331–6 d/mFrovatriptan, almotriptan 2.5 mg, 12.5 mg  Ranking10
Gonzalez et al. [36]2013aAmericanCross-sectional510      SG8
Smelt et al. [37]2014aNetherlandsCross-sectional300 Triptans, ergotamine, analgesics    Ranking8
TTO, time trade-off; SG, standard gamble. aThe date are year of publication, because survey dates were not reported.